Closure of Trading Window
As per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from March 24, 2017 to May 15, 2017 (both days inclusive) for the purpose of approval of Standalone and Consolidated Audited Financial Results for the Year ended March 31, 2017. Board Meeting On May 11, 2017
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations And Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, May 11, 2017 to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the year ended March 31, 2017. Glenmark starts clinical trial for biosimilar used to treat allergic asthma
The reference product for this biosimilar is omalizumab, sold under the brand name Xolair Press Release
Glenmark Pharmaceuticals Initiates Clinical Investigation for GBR 310, its Proposed Biosimilar Candidate for XOLAIR With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. Glenmark plans new launches in US, receives FDA nod for anticoagulant drug
Pradaxa is Glenmark's fourth product approval in the US from January till date Press Release
Sub:- Glenmark Pharmaceuticals receives tentative ANDA approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg and 150 mg With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. Thanking You. Yours faithfully, For Glenmark Pharmaceuticals Ltd. Harish Kuber Company Secretary & Compliance Officer Certificate From Practicing Company Secretary Under Regulation 40(9) Of The SEBI Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2017
Enclosed please find herewith the copy of the certificate issued by M/s. Savita Jyoti Associates, Company Secretaries under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Half Yearly ended 31st March, 2017. Please take the same on records. Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2017.
Enclosed please find herewith the Compliance Certificate under Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Half Yearly ended 31st March, 2017. Please take the same on records. Shareholding for the Period Ended March 31, 2017
Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here